[ Price : $8.95]
Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Innate Pharmas Lumoxiti.[ Price : $8.95]
Federal Register notice: FDA seeks comments on an information collection extension for Adverse Experience Reporting For Licensed B...[ Price : $8.95]
FDA warns Mylan about CGMP deviations in producing active pharmaceutical ingredients at one of its facilities in India.[ Price : $8.95]
FDA warns Acella Pharmaceuticals about CGMP and other violations in its production of finished drugs.[ Price : $8.95]
Two drug company stakeholders respond to an FDA draft guidance on Orange Book questions and answers.[ Price : $8.95]
Attorney Jeffrey Shapiro discusses reasons why HHS made the right decision in ordering FDA to abstain from the premarket review of...[ Price : $8.95]
FDA releases its latest batch of Warning Letters that includes Acella Pharmaceuticals, Mylan and Revival Products.[ Price : $8.95]
An assessment finds that combination product review practices are generally efficient and effective and need only minor adjustment...